What is the share price of Hemo Organic Ltd (HEMORGANIC) today?
The share price of HEMORGANIC as on 7th September 2026 is ₹18.91. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Hemo Organic Ltd (HEMORGANIC) share?
The past returns of Hemo Organic Ltd (HEMORGANIC) share are- Past 1 week: 5.23%
- Past 1 month: -9.69%
- Past 3 months: -15.16%
- Past 6 months: 25.82%
- Past 1 year: 81.83%
- Past 3 years: 176.06%
- Past 5 years: 75.25%
What are the peers or stocks similar to Hemo Organic Ltd (HEMORGANIC)?
The peers or stocks similar to Hemo Organic Ltd (HEMORGANIC) include:What is the market cap of Hemo Organic Ltd (HEMORGANIC) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hemo Organic Ltd (HEMORGANIC) is ₹14.38 Cr as of 7th September 2026.What is the 52 week high and low of Hemo Organic Ltd (HEMORGANIC) share?
The 52-week high of Hemo Organic Ltd (HEMORGANIC) is ₹24.42 and the 52-week low is ₹8.12.What is the PE and PB ratio of Hemo Organic Ltd (HEMORGANIC) stock?
The P/E (price-to-earnings) ratio of Hemo Organic Ltd (HEMORGANIC) is -18.67. The P/B (price-to-book) ratio is 110.59.Which sector does Hemo Organic Ltd (HEMORGANIC) belong to?
Hemo Organic Ltd (HEMORGANIC) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Hemo Organic Ltd (HEMORGANIC) shares?
You can directly buy Hemo Organic Ltd (HEMORGANIC) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Hemo Organic Ltd
HEMORGANIC Share Price
BSE₹18.910.00% (+0.00)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
HEMORGANIC Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
HEMORGANIC Performance & Key Metrics
HEMORGANIC Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -18.92 | 110.59 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.35 | 5.84 | 0.49% |
HEMORGANIC Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
HEMORGANIC Company Profile
Hemo Organic is engaged in manufacturing of ayurvedic medicines.
SUNPHARMA
PE Ratio
39.76
39.76
1Y Return
14.31%
14.31%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
86.09
86.09
1Y Return
38.56%
38.56%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.83
29.83
1Y Return
12.48%
12.48%
Buy Reco %
62.86
62.86
ZYDUSLIFE
PE Ratio
22.17
22.17
1Y Return
7.23%
7.23%
Buy Reco %
57.69
57.69
LUPIN
PE Ratio
18.88
18.88
1Y Return
5.38%
5.38%
Buy Reco %
51.52
51.52
HEMORGANIC Forecast
HEMORGANIC Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
HEMORGANIC
HEMORGANIC
Income
Balance Sheet
Cash Flow
Quarterly Normal View
HEMORGANIC Income Statement
HEMORGANIC Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.02 | 0.00 | 0.00 | 0.00 | 2.50 | 0.00 | 0.00 | 0.00 | 0.93 | 0.00 | ||||||||||
Operating & Other expenses | 0.23 | 0.00 | 0.08 | 0.08 | 2.27 | 0.12 | 0.04 | 0.05 | 1.22 | 0.07 | ||||||||||
EBITDA | -0.21 | 0.00 | -0.08 | -0.08 | 0.23 | -0.12 | -0.04 | -0.05 | -0.29 | -0.07 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBIT | -0.21 | 0.00 | -0.08 | -0.08 | 0.23 | -0.12 | -0.04 | -0.05 | -0.29 | -0.07 | ||||||||||
| Interest & Other Items | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| PBT | -0.23 | 0.00 | -0.08 | -0.08 | 0.23 | -0.12 | -0.04 | -0.05 | -0.29 | -0.07 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | -0.14 | -0.03 | -0.01 | 0.11 | 0.21 | 0.00 | ||||||||||
| Net Income | -0.23 | 0.00 | -0.08 | -0.08 | 0.37 | -0.09 | -0.03 | -0.16 | -0.50 | -0.07 | ||||||||||
| EPS | -0.67 | -0.01 | -0.23 | -0.23 | 1.08 | -0.25 | -0.09 | -0.45 | -1.46 | -0.21 |
HEMORGANIC Company Updates
HEMORGANIC Stock Peers
HEMORGANIC Past Performance & Peer Comparison
HEMORGANIC Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Hemo Organic Ltd | -18.67 | 110.59 | — |
| Sun Pharmaceutical Industries Ltd | 39.76 | 5.44 | 0.84% |
| Torrent Pharmaceuticals Ltd | 86.09 | 10.59 | 0.69% |
| Cipla Ltd | 29.83 | 3.35 | 0.91% |
HEMORGANIC Stock Price Comparison
Compare HEMORGANIC with any stock or ETFCompare HEMORGANIC with any stock or ETF
HEMORGANIC
HEMORGANIC Holdings
HEMORGANIC Shareholdings
HEMORGANIC Promoter Holdings Trend
HEMORGANIC Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
HEMORGANIC Institutional Holdings Trend
HEMORGANIC Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.84%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
HEMORGANIC Shareholding Pattern
HEMORGANIC Shareholding Pattern
HEMORGANIC Shareholding History
HEMORGANIC Shareholding History
Foreign Institutions
smallcases containing HEMORGANIC stock
smallcases containing HEMORGANIC stock
Looks like this stock is not in any smallcase yet.
HEMORGANIC Events
HEMORGANIC Events
HEMORGANIC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HEMORGANIC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
HEMORGANIC Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
HEMORGANIC has not given any dividends in last 5 years
HEMORGANIC Dividends
HEMORGANIC Dividends
Hmm, looks like data is unavailable here. Please come back after some timeHEMORGANIC Stock News & Opinions
HEMORGANIC Stock News & Opinions
Articles & Videos
Corporate
Corporate
Hemo Organic Limited named V S S B & Associates as auditor for five yearsHemo Organic Limited announced that members approved the appointment of M/s. V S S B & Associates as the Statutory Auditor for a term of five years, effective from the conclusion of the 34th Annual General Meeting held on September 9, 2026, replacing M/s M A A K & Associates, whose second term concluded at the same meeting.
4 days agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited appoints Ayush Jasani as Additional Director and ChairpersonHemo Organic Limited announced the appointment of Mr. Ayush Dharmendrabhai Jasani (DIN: 09842741) as an Additional Director and Chairperson of the company, effective September 9, 2026, following a board meeting held on the same date. Mr. Jasani, who is a Non-Executive and Non-Independent Director, is a matriculate from the Gujarat Secondary and Higher Secondary Education Board and has experience in the business of hiring and leasing earth moving equipment.
4 days agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited shareholders appointed V S S B & Associates as auditor for five yearsHemo Organic Limited announced that members approved the appointment of M/s. V S S B & Associates as the Statutory Auditor for a term of five years, effective from the conclusion of the 34th Annual General Meeting held on September 9, 2026, replacing M/s M A A K & Associates, whose second term concluded at the same meeting.
5 days agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited names Ayush Jasani as Additional Director and ChairpersonHemo Organic Limited announced the appointment of Mr. Ayush Dharmendrabhai Jasani (DIN: 09842741) as an Additional Director and Chairperson of the company, effective September 9, 2026, subject to member approval.
5 days agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited closes share books August 7-September 8 for its annual meetingHemo Organic Limited informed the BSE Limited that the register of members and share transfer books will remain closed from September 1, 2026, to September 8, 2026, with a cut-off date of August 7, 2026, for the purpose of the 34th Annual General Meeting and to determine shareholders eligible to participate in e-voting.
1 month agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited appointed V S S B & Associates as statutory auditor for five yearsHemo Organic Limited informed the BSE that its board approved the appointment of M/s. V S S B & Associates, Chartered Accountant, as the company's statutory auditor for a five-year term, starting after the conclusion of the 34th Annual General Meeting and ending at the conclusion of the 39th Annual General Meeting, subject to shareholder approval. The current statutory auditor, M/s. M A A K & Associates, Chartered Accountant, will expire at the conclusion of the 34th Annual General Meeting. Additionally, the company scheduled its 34th Annual General Meeting for Tuesday, September 8, 2026, at 3:00 P.M. through Video Conferences/Other Audio-Visual Means.
1 month agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited’s statutory auditors, M/s. M A A K & Associates, will retire in 2026Hemo Organic Limited informed the BSE that M/s. M A A K & Associates, Chartered Accountants (FRN: 135024W) have completed their maximum permissible tenure as statutory auditors of the company, and will retire from the position upon the conclusion of the 34th Annual General Meeting to be held on September 8, 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited appointed V S S B & Associates as statutory auditor for five yearsHemo Organic Limited informed the BSE that its board approved the appointment of M/s. V S S B & Associates, Chartered Accountant, as the company's statutory auditor for a five-year term, starting after the conclusion of the 34th Annual General Meeting and ending at the conclusion of the 39th Annual General Meeting, subject to shareholder approval. The current statutory auditor, M/s. M A A K & Associates, Chartered Accountant, will expire at the conclusion of the 34th Annual General Meeting. Additionally, the company scheduled its 34th Annual General Meeting for Tuesday, September 8, 2026, at 3:00 P.M. through Video Conferences/Other Audio-Visual Means.
1 month agoCapital Market - Live
Corporate
Corporate
Hemo Organic Limited appointed auditors Jitendra Parmer & Associates and Umesh Khese & CoHemo Organic Limited appointed M/s. Jitendra Parmer & Associates as Secretarial Auditor for the financial year 2025-26 and M/s. Umesh Khese & Co. as Internal Auditor for the financial year 2026-27, according to a filing with the BSE Limited on August 4, 2026. The appointments were made to comply with the Companies Act, 2013 and the requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
1 month agoCapital Market - Live
Earnings
Earnings
Hemo Organic reports standalone net loss of Rs 0.07 crore in the June 2026 quarterNet Loss of Hemo Organic reported to Rs 0.07 crore in the quarter ended June 2026 as against net loss of Rs 0.09 crore during the previous quarter ended June 2025. There were no Sales reported in the quarter ended June 2026 and during the previous quarter ended June 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 147.57%, vs industry avg of 11.78%
Over the last 5 years, market share stayed at 0%